Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
148,28 €
-0,34 %
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.
